{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Muecksch F"],"funding":["NIAID NIH HHS","National Rosacea Society","National Institutes of Health"],"pagination":["e493-e502"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9141682"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(7)"],"pubmed_abstract":["Background
Serological assays are being used to monitor antibody responses in individuals who had SARS-CoV-2 infection and those who received a COVID-19 vaccine. We aimed to determine whether such assays can predict neutralising antibody titres as antibody levels wane and viral variants emerge.Methods
We measured antibody levels in serum samples from a cohort of 112 participants with SARS-CoV-2 infection using ten high-throughput serological tests and functional neutralisation assays. Serum samples were taken at baseline and at up to four subsequent visits. We assessed the effects of time and spike protein sequence variation on the performance and predictive value of the various assays. We did correlation analyses for individual timepoints using non-parametric Spearman corr"],"journal":["The Lancet. Microbe"],"pubmed_title":["Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis."],"pmcid":["PMC9141682"],"funding_grant_id":["SR1407","R01AI78788","R01 AI078788","R01 AI050111","R01 AI50111"],"pubmed_authors":["Malloy K","Zhang F","Hatziioannou T","Schmidt F","Jenks S","McCance K","Squires M","Mavin S","Templeton K","Muecksch F","Batchelor B","Bieniasz PD","Richardson C","Burns A","Furrie E","Godber I","Jarvis L","MacGuire J","Wise H"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis.","description":"Background
Serological assays are being used to monitor antibody responses in individuals who had SARS-CoV-2 infection and those who received a COVID-19 vaccine. We aimed to determine whether such assays can predict neutralising antibody titres as antibody levels wane and viral variants emerge.Methods
We measured antibody levels in serum samples from a cohort of 112 participants with SARS-CoV-2 infection using ten high-throughput serological tests and functional neutralisation assays. Serum samples were taken at baseline and at up to four subsequent visits. We assessed the effects of time and spike protein sequence variation on the performance and predictive value of the various assays. We did correlation analyses for individual timepoints using non-parametric Spearman corr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-22T11:49:31.426Z","creation":"2025-04-06T00:07:42.349Z"},"accession":"S-EPMC9141682","cross_references":{"pubmed":["35636436"],"doi":["10.1016/S2666-5247(22)00090-8"]}}